Clinical Study

Rrx-001-211-01- A Phase II Study Of Rrx-001 In Platinum Refractory/Resistant Small Cell Lung Cancer, Egfr Tki Resistant Egfr+ T790m Negative Non-Small Cell

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Specialties: Cancer, Lung Cancer, Oncology, Ovarian Cancer
  • Type of Study: Drug

To evaluate Overall Survival (OS) and Overall Response Rate (ORR) of RRx-001 in patients with high-grade neuroendocrine carcinoma, non-small cell lung cancer, and ovarian cancer previously treated with a platinum based regimen.


To Be Eligible: Must Have Neuroendorcrine Carcinoma, Nsclc, Or Ovarian Cancer, Age 18 Or Older, Life Expectancy Over 12 Weeks, Nonpregnant/Breastfeeding


Lung Cancer, Ovarian Cancer, Neuroendocrine, Rrx001-211-01

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.